Dengue Vaccine Market
Market Overview
Pharmanucleusanalyzes a growth rate of the Dengue Vaccine market over the forecast period 2023-2030. The expected CAGR of the dengue fever vaccine market tends to be around 11.7% during the mentioned forecast period. The market was valued at USD 0.53 Billion in 2022 and it will reach USD 1.28 Billion by 2030. Along with market insights such as market value, growth rate, market segments, coverage geography, market players, and market scenario, the market report curated by the Pharmanucleus team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, price analysis, and framework regulatory.
Market Analysis and Size
The dengue vaccine is only recommended for people who have had dengue fever in the past. It is given in three injections spread over a year. A vaccine to prevent dengue fever (Dengvaxia) has been licensed and is available in some countries for people aged 9-45. The Developing Countries Vaccine Manufacturers Network (DCVMN) is gaining popularity due to its growing capacity and willingness to effectively advance the clinical development of vaccines.
Market Definition
Dengue fever is a prevalent tropical illness that is caused by the dengue virus and transmitted through mosquito bites. The symptoms of dengue fever typically manifest within 3 to 14 days after a person is infected. Common symptoms include nausea, high body temperature, muscle and joint pain, severe headache, and a distinct skin rash.
The dengue virus is primarily transmitted by the Aedes mosquito, particularly the Aedes aegypti species, which thrives in tropical and subtropical regions. When an infected mosquito bites a person, the virus enters the bloodstream, leading to the onset of dengue fever.
While there is no specific treatment for dengue fever, supportive care such as rest, fluid intake, and pain relievers can help alleviate the symptoms. However, in severe cases, dengue fever can progress to a life-threatening condition called dengue hemorrhagic fever or dengue shock syndrome, which may require hospitalization and specialized medical care.
The World Health Organization (WHO) recommends that the dengue vaccine should only be administered to individuals who have a confirmed history of dengue virus infection. This precaution is due to the risk of severe complications if the vaccine is given to individuals who have not been previously infected with the virus. The vaccine aims to provide protection against future dengue infections for those who have already experienced the disease.
In areas where dengue fever is prevalent, preventive measures such as using mosquito repellents, wearing protective clothing, and eliminating mosquito breeding sites are crucial in reducing the transmission of the virus. Public health efforts also focus on mosquito control strategies and raising awareness about dengue prevention and early detection to mitigate the impact of this disease.
Dengue Vaccine Market Dynamics
Drivers
- Increasing Incidence of Dengue
The rising prevalence of dengue fever is expected to drive growth in the dengue vaccine market over the forecast period. For example, the Pan American Health Organisation reported 1,191,815 dengue cases in the Americas area between epidemiological week 1 and 22 of 2019, of which 546,589 were laboratory-confirmed and 5,599 were classed as severe dengue. As a result, the need for vaccinations rises.
- Growing R&D Activities
Engagement in R&D for vaccine development is one of the most essential strategies for gaining a competitive advantage in the dengue vaccine market. Ongoing research holds promising potential for the development of next-generation vaccines against dengue, malaria and tuberculosis. Several R&D of live attenuated vaccines are also expected to contribute to the market growth. For example, in May 2019 the US FDA approved Dengvaxia used for the prevention of dengue fever caused by all dengue virus serotypes. It is a tetravalent live attenuated chimeric vaccine that is manufactured using recombinant DNA technology. Additionally, Panacea Biotec, an India-registered global generic and specialty pharmaceutical and vaccine manufacturer, has successfully completed the Phase I/II study of its novel chimeric tetravalent dengue vaccine candidate candidateDengiAll.
Opportunities
- Increased Initiatives by Several Organizations
Some organizations have led to the development of several useful vaccines to eliminate dengue fever. For example, the Department of Biotechnology in India is leading concerted efforts to strengthen vaccine R&D through its Vaccine Action Program. As part of this initiative, the Indo-US Vaccine Action Program (VAP) was launched in 2017. It is a bilateral program developed by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) within the Department of Health and Human Services, USA and the Department of Biotechnology (DBT), Ministry of Science and Technology, Government of India, in collaboration with the Human Immunology Project Consortium (HIPC).
Restraints/Challenges
- Lack of Understanding the Differences
The increasing inability to distinguish dengue fever from other febrile infections is projected to stymie industry expansion. The symptoms of mosquito-borne infections like Zika, chikungunya virus infection, and dengue fever, for example, are remarkably similar, making diagnosis challenging. Furthermore, the lack of understanding of dengue infection pathophysiology and the absence of appropriate animal models are projected to stymie market expansion.
- Unavailability of Vaccinations
The growth of the dengue vaccine market is being hindered by the high unavailability of vaccines, particularly in underdeveloped areas. This lack of access to vaccines prevents populations in these regions from effectively coping with dengue epidemics, thereby hampering the market's growth.
The unavailability of dengue vaccines in underdeveloped areas is a significant challenge. Dengue fever is prevalent in many tropical and subtropical regions, where healthcare resources may be limited. The absence of vaccines leaves these populations vulnerable to dengue infections and their associated risks.
The limited availability of vaccines also affects the market's expansion. The demand for dengue vaccines is high, given the burden of the disease and the need for preventive measures. However, the inability to meet this demand due to vaccine unavailability prevents the market from growing at its full potential.
In addition to the availability issue, the content mentions a Dengue Vaccine Market report. This report likely provides comprehensive information about the market, including recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, and the impact of national and localized market players. It may also cover opportunities for revenue growth, changes in market regulations, strategic market analysis, market size, category market growth, and technological innovations.
To gain more insights on the Dengue Vaccine Market, the content suggests contacting Pharmanucleus for an Analysis Note. Their team can assist in making informed market decisions to achieve market growth, leveraging the information provided in the market report.
Recent Development:
In 2021, Takeda Pharmaceutical Company Limited made an important announcement regarding its dengue vaccine candidate, TAK-003. The European Medicines Agency (EMA) granted approval for this vaccine, which is currently being evaluated for its effectiveness in preventing dengue epidemics among individuals aged 4 to 60 years.
This approval marked a significant milestone in the development of a dengue vaccine, as dengue fever is a major public health concern in many parts of the world, particularly in tropical and subtropical regions. The availability of an effective vaccine could potentially help reduce the burden of dengue and its associated complications.
Following the EMA approval, Takeda Pharmaceutical Company Limited outlined its plans to seek regulatory licenses for the TAK-003 vaccine in several countries. These countries include Argentina, Brazil, Colombia, Indonesia, Malaysia, Mexico, Singapore, Sri Lanka, and Thailand. By seeking regulatory approval in these countries, Takeda aims to make the vaccine accessible to populations that are at risk of dengue infection.
The process of seeking regulatory licenses involves rigorous evaluation of the vaccine's safety, efficacy, and manufacturing processes. It requires close collaboration with regulatory authorities in each country to ensure that the vaccine meets the necessary standards for public health use.
Takeda's efforts in developing and seeking approval for the TAK-003 dengue vaccine candidate demonstrate a commitment to addressing the global burden of dengue fever. If approved and implemented, this vaccine has the potential to make a significant impact in reducing the incidence and severity of dengue infections in the future.
Dengue Vaccine Market Scope
Dengue vaccine sales are classified by kind, therapy, mode of administration, distribution channel, and end-user. The growth in these segments will assist you in analysing the growth sectors in industries and providing users with a beneficial market overview and industry insights to assist them in making strategic decisions for finding key market applications.
Type
- Live Attenuated Vaccine
- Chimeric Live Attenuated Vaccine
- Inactivated Vaccine
- Subunit Vaccine
- Nucleic Acid Based Vaccine
Treatment
- Diuretic
- Chlorothiazide
- Chlorthalidone
- Hydrochlorothiazide
- Indapamide
- Anti-Allergic
- Cetirizine
- Desloratadine
- Fexofenadine
- Blood Thinners
- Apixaban
- Dabigatran
- Edoxaban
- Others
Route of Administration
- Oral
- Parenteral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Regional Analysis/Insights
Dengue Vaccine market is analyzed and market size insights and trends are provided by type, treatment, route of administration, distribution channel and end-user as discussed above.
North America has witnessed positive dengue vaccine market growth throughout the forecast period owing to the presence of major key players and increased prevalence of dengue fever.
Asia-Pacific is dominating the market owing to the increase in government spending for the development of better healthcare infrastructure in the region.
The country section of the report also provides individual market impacting factors and regulatory changes in the national market that impact current and future market trends. In addition, the presence and availability of global brands and the challenges they face due to significant or rare competition from local and national brands, the impact of domestic tariffs and trade routes are considered while providing a forecast analysis of national data.
Competitive Landscape
Dengue Vaccine Market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, research and development investment, new market initiatives, global presence, locations and production facilities, production capacities, company strengths and weaknesses, product launch, product breadth and breadth, application dominance. The data points above provided are only related to the focus of the companies on the dengue vaccine market
Key players operating in the dengue vaccine market include:
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Novartis AG (Switzerland)
- GSK plc (U.K.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Takeda Pharmaceutical Company Limited (Japan)
- BIO-MED (India)
- Intercept Pharmaceuticals, Inc (U.K.)
- Emcure Pharmaceuticals Limited (India)
- Changchun BCHT Biotechnology Co. (China)
Novo Medi Sciences (India)